[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-338198-105":3,"detail-sidebar-cat-0-en-105":73,"doc-detail-338198-en":122},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":66,"head_meta":68,"extra_data":70,"updated_unix":72},105,"en","mta-cooperative-prmt5-inhibitors-enhance-t-cell-mediated-antitumor-activity-in-mtap-loss-tumors","MTA-cooperative PRMT5 inhibitors enhance T cell-mediated antitumor activity in MTAP-loss tumors","","Hyperactivated PRMTs drive human cancers, and prior work suggested that inhibiting tumor-intrinsic PRMT5 can amplify antitumor immunity. However, broad PRMT5 suppression also harms effector functions of immune cells. This study identifies approaches to inhibit PRMT5 specifically in tumor tissue and develops PRMT5i-based immuno-oncology combinations for MTAP-loss cancers. Strategies were tested in isogenic models using PRMT5 inhibitors, with transcriptomic and proteomic profiling and evaluation with immune checkpoint blockade.",{"@graph":14,"@context":65},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/mta-cooperative-prmt5-inhibitors-enhance-t-cell-mediated-antitumor-activity-in-mtap-loss-tumors/338198/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/mta-cooperative-prmt5-inhibitors-enhance-t-cell-mediated-antitumor-activity-in-mtap-loss-tumors/338198.png","ImageObject",300,407,{"name":42,"@type":43},"Miles","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-12","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59],{"name":60,"@type":61,"acceptedAnswer":62},"What combination therapy improved antitumor activity in MTAP-loss tumor models?","Question",{"text":63,"@type":64},"Combining MRTX1719 with anti-PD-1 produced superior antitumor activity in mice bearing MTAP-loss tumors, supporting an effective immuno-oncology combination strategy.","Answer","https://schema.org",{"og:url":32,"og:type":67,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":69,"canonical":32},"index,follow",{"doc_id":71,"site_id":7},338198,1790417801,{"code":4,"msg":74,"data":75},"success",[76,80,84,88,93,98,102,106,111,114,118],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":77,"show_sort_weight":78,"slug":79},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":81,"show_sort_weight":82,"slug":83},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Exam",70,"exam",{"id":89,"doc_module":4,"doc_module_name":25,"category_name":90,"show_sort_weight":91,"slug":92},5,"Comic",60,"comic",{"id":94,"doc_module":4,"doc_module_name":25,"category_name":95,"show_sort_weight":96,"slug":97},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":99,"show_sort_weight":100,"slug":101},"Healthcare",40,"healthcare",{"id":103,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":104,"slug":105},8,30,"research-report",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},9,"Religion & Spirituality",20,"religion-spirituality",{"id":109,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":109,"slug":113},"World Cup","world-cup",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":115,"slug":117},10,"Lifestyle","lifestyle",{"id":119,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":89,"slug":121},19,"General","general",{"code":4,"msg":74,"data":123},{"doc_id":71,"user_id":124,"nickname":42,"user_avatar":125,"doc_module":4,"category_id":103,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":126,"file_id":127,"file_url":128,"file_type":129,"file_size":130,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":131,"language":132,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":133,"faqs":134,"seo_title":135,"seo_description":12,"update_tm":136,"read_time":137,"preview_page_count":33,"preview_urls":138},13056703019404,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Open access Original research  \n MTA-cooperative PRMT5 inhibitors  \nenhance T cell-mediated antitumor activity in MTAP-loss tumors  \nSi Chen,1 Jiakai Hou,1 Roshni Jaffery,1 Ashley Guerrero,1 Rongjie Fu,2 Leilei Shi,2 Ningbo Zheng,1 Ritu Bohat,1 Nicholas A Egan,1 Chengtai Yu,1 Sana Sharif,3 Yue Lu,2 Wei He,2 Shuyue Wang,2 Donjeta Gjuka,4 Everett M Stone,4  \nPooja Anil Shah,5 Jordi Rodon Ahnert,5 Taiping Chen,2 Xinli Liu,3 Mark T Bedford,2 Han Xu,2 Weiyi Peng  1  \nTo cite: Chen S, Hou J, Jaffery R, et al. MTAcooperative PRMT5 inhibitors enhance T cell-mediated antitumor activity in MTAPloss tumors. Journal for ImmunoTherapy of Cancer 2024;12:e009600 . doi:10 . 1136/ jitc-2024-009600  \n► Additional supplemental material is published online only. To view, please visit the journal online ([https://doi.org/10.1136/](https://doi.org/10.1136/)[ ](https://doi.org/10.1136/)[jitc-2024-009600](jitc-2024-009600)) .  \nAccepted 06 September 2024  \n© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.  \n1Biology and Biochemistry, University of Houston, Houston, Texas, USA  \n2Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA 3Pharmacological and Pharmaceutical Sciences, University of Houston, Houston, Texas, USA  \n4Molecular Biosciences, The University of Texas at Austin, Austin, Texas, USA 5Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA  \nCorrespondence to  \nDr Weiyi Peng;  \n[wpeng2@central.uh.edu](wpeng2@central.uh.edu)  \nABSTRACT  \nBackground Hyperactivated protein arginine methyltransferases (PRMTs) are implicated in human cancers. Inhibiting tumor intrinsic PRMT5 was reported to potentiate antitumor immune responses, highlighting the possibility of combining PRMT5 inhibitors (PRMT5i) with cancer immunotherapy. However, global suppression of PRMT5 activity impairs the effector functions of immune cells. Here, we sought to identify strategies to specifically inhibit PRMT5 activity in tumor tissues and develop effective PRMT5i-based immunooncology (IO) combinations for cancer treatment, particularly for methylthioadenosine phosphorylase (MTAP)-loss cancer.  \nMethods Isogeneic tumor lines with and without MTAP loss were generated by CRISPR/Cas9 knockout. The effects of two PRMT5 inhibitors (GSK3326595 and MRTX1719) were evaluated in these isogenic tumor lines and T cells in vitro and in vivo. Transcriptomic and proteomic changes in tumors and T cells were characterized in response to PRMT5i treatment. Furthermore, the efficacy of MRTX1719 in combination with immune checkpoint blockade was assessed in two syngeneic murine models with MTAP-loss tumor.  \nResults GSK3326595 significantly suppresses PRMT5 activity in tumors and T cells regardless of the MTAP status. However, MRTX1719, a methylthioadenosinecooperative PRMT5 inhibitor, exhibits tumor-specific PRMT5 inhibition in MTAP-loss tumors with limited immunosuppressive effects. Mechanistically, transcriptomic and proteomic profiling analysis reveals that MRTX1719 successfully reduces the activation of the PI3K pathway, a well-documented immune-resistant pathway. It highlights the potential of MRTX1719 to overcome immune resistance in MTAP-loss tumors. In addition, MRTX1719 sensitizes MTAP-loss tumor cells to the killing of tumor-reactive T cells. Combining MRTX1719 and anti-PD-1 leads to superior antitumor activity in mice bearing MTAP-loss tumors.  \nConclusion Collectively, our results provide a strong rationale and mechanistic insights for the clinical development of MRTX1719-based IO combinations in MTAP-loss tumors.  \nWHAT IS ALREADY KNOWN ON THIS TOPIC  \n\n| ⇒ Loss of MTAP is one of the most frequently observed somatic alterations in human cancers, particularly in patients with 9p21 focal copy number deletion. Recent studies suggest that MTAP loss contributes to altering numerous ","cbCaiif2uXWet8bT","https://ap.wps.com/l/cbCaiif2uXWet8bT","pdf",5918125,14,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# What is already known on this topic\n# What this study adds\n# How this study might affect research, practice or policy\n# Background","[{\"question\":\"What combination therapy improved antitumor activity in MTAP-loss tumor models?\",\"answer\":\"Combining MRTX1719 with anti-PD-1 produced superior antitumor activity in mice bearing MTAP-loss tumors, supporting an effective immuno-oncology combination strategy.\"}]","MTA-cooperative PRMT5 inhibitors enhance T cell-mediated antitumor activity in MTAP-loss tumors | PDF",1790022484,35,[139,143,147,151],{"page_no":22,"url":140,"width":141,"height":142},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d41e5eecc3a42030faa2c80c174045cb.webp",983,1310,{"page_no":26,"url":144,"width":145,"height":146},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/aaea97a256e785d5b8d52eedda17f333.webp",982,1309,{"page_no":30,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/120b767813df97a466b2a3789e613ae5.webp",981,1308,{"page_no":33,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dec55c00d242a512ec04181f73122c1e.webp",980,1306]